Takeaways From FTC Settlement With Cardinal Health
Law360, New York (May 13, 2015, 12:01 PM EDT) -- On April 20, 2015, the Federal Trade Commission announced a proposed settlement[1] of allegations that Cardinal Health Inc. used its monopoly power in 25 local markets to exclude potential entrants by obtaining de facto exclusive rights to distribute a key pharmaceutical. The FTC alleged that Cardinal engaged in a variety of tactics to ensure that the only two suppliers of this product refused to distribute to potential competitors. Cardinal agreed to a $26.8 million penalty for ill-gotten gains as a result of its conduct, as well as injunctive relief to prevent future violations and to restore competition in six local markets. The disgorgement penalty is the second largest financial award that the FTC has ever obtained for a violation of the antitrust laws....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
